Efrat Shema
About Efrat Shema
Efrat Shema is a Research Fellow and Principal Investigator at the Weizmann Institute of Science, focusing on single-molecule technologies and epigenetic regulation in development and cancer. She has extensive experience at leading institutions, including Massachusetts General Hospital, Harvard Medical School, and the Broad Institute.
Work at Broad Institute
Efrat Shema has been serving as a Research Fellow at the Broad Institute since 2012. During her tenure, she has engaged in advanced research focusing on the application of single-molecule technologies to study chromatin. Her work contributes to the understanding of epigenetic regulation, particularly in the context of early development and cancer. The Broad Institute, located in Cambridge, MA, is renowned for its collaborative approach to biomedical research, and Shema's role aligns with its mission to advance scientific knowledge.
Current Positions
Efrat Shema holds multiple research positions concurrently. Since 2012, she has been a Research Fellow at Massachusetts General Hospital and Harvard Medical School, in addition to her role at the Broad Institute. In 2017, she became a Principal Investigator (Assistant Professor) at the Weizmann Institute of Science in Rehovot, Israel. Her diverse roles allow her to integrate her research on epigenetic regulation across various prestigious institutions.
Education and Expertise
Efrat Shema earned her Doctor of Philosophy (Ph.D.) in Molecular Biology and Epigenetics from the Weizmann Institute of Science, completing her studies from 2005 to 2012. Prior to this, she obtained a Bachelor of Science (B.Sc.) in Biology from The Hebrew University of Jerusalem, where she studied from 2002 to 2005. Her educational background provides a strong foundation for her research in epigenetic regulation and single-molecule technologies.
Research Focus
Efrat Shema's research aims to harness single-molecule technologies for clinical applications. She focuses on understanding the complex network of epigenetic regulation during early development and its implications in cancer. By developing and applying novel single-molecule technologies, she studies chromatin dynamics, contributing to the broader understanding of gene regulation and its effects on health and disease.